What Is Clinical Relevance in Clinical Trials?

Clinical trial results are often judged by a simple question: was the result statistically significant?

While statistical significance remains a cornerstone of clinical research, it is rarely the question that matters most to patients, clinicians, HTA bodies, or regulators. Their focus is usually broader. They want to know whether a treatment provides a meaningful benefit in real-world practice. In other words, they want to understand its clinical relevance.

This distinction is becoming increasingly important as healthcare decision-makers move beyond individual trial endpoints and place greater emphasis on patient experience, treatment trade-offs, and overall clinical value. As a result, clinical relevance has become one of the most important, yet often misunderstood, concepts in clinical development.

What is clinical relevance?

Clinical relevance refers to the extent to which a treatment effect matters in practice.

A statistically significant result tells us that an observed difference is unlikely to be due to chance. Clinical relevance tells us whether that difference is meaningful enough to influence treatment decisions or improve patient outcomes.

For example, a treatment may demonstrate a statistically significant improvement in progression-free survival. However, if that improvement is very small and comes at the cost of substantial toxicity, clinicians may question whether the overall benefit is meaningful for patients.

Conversely, some treatment effects may have a profound impact on symptoms, daily functioning, or quality of life even when these outcomes receive less attention than traditional efficacy endpoints.

Clinical relevance therefore goes beyond the question of whether a treatment works. It asks whether the treatment makes a meaningful difference.

Why statistical significance is not enough

The history of clinical trials has understandably focused on demonstrating efficacy through predefined endpoints and hypothesis testing. These tools remain essential. Without them, it would be impossible to distinguish genuine treatment effects from random variation.

The challenge is that patients do not experience a treatment through a single endpoint.

A patient does not experience overall survival separately from toxicity. Quality of life is not experienced independently from disease control. Treatment burden, symptoms, safety, and efficacy all interact to shape the overall value of a therapy.

Yet clinical trials often analyse these outcomes independently. One table may describe efficacy results, another adverse events, and another quality-of-life findings. While each analysis provides valuable information, decision-makers are ultimately left with the challenge of interpreting how all these outcomes fit together.

That interpretation is the foundation of clinical relevance.

Clinical relevance requires the totality of evidence

When clinicians evaluate a treatment, they rarely focus on a single result in isolation. They consider the broader evidence package.

Will the treatment improve survival? Does it reduce symptoms? Can it preserve quality of life? Are the toxicities manageable? Which patients benefit the most?

The answers to these questions collectively determine whether a treatment is clinically relevant.

This is why discussions around the totality of evidence have become increasingly prominent in regulatory review, Health Technology Assessment, and Joint Clinical Assessment under the EU HTAR. The goal is not simply to identify significant results, but to develop a coherent understanding of overall treatment value.

The challenge, however, is that treatment effects often involve trade-offs. Some outcomes favour the new treatment while others favour the comparator. Different stakeholders may also prioritise outcomes differently.

This raises an important question: how can the totality of evidence be evaluated in a transparent and reproducible way?

Can clinical relevance be measured?

Traditionally, assessments of clinical relevance have relied heavily on expert judgement. Clinical experts review efficacy and safety findings, consider patient impact, and ultimately reach conclusions regarding overall treatment value.

This approach remains essential. Clinical relevance cannot be reduced to a single number.

However, there is growing interest in methodologies that can support these evaluations by examining multiple clinically important outcomes simultaneously rather than one at a time.

One example is Net Treatment Benefit (NTB), a methodology derived from Generalized Pairwise Comparisons.

Rather than focusing on a single endpoint, NTB allows multiple outcomes to be incorporated into a clinically meaningful hierarchy. Survival, disease progression, serious adverse events, and quality of life can all contribute to the overall evaluation.

This shifts the conversation from asking whether a treatment improved one specific outcome to asking a more clinically relevant question:

When all important outcomes are considered together, which treatment provides the better overall result for patients?

That question is often much closer to the decisions made by clinicians, patients, regulators, and HTA bodies in practice.

Clinical relevance in modern evidence generation

The importance of clinical relevance continues to grow across the healthcare landscape.

Regulators increasingly encourage evidence generation strategies that move beyond isolated efficacy measures. HTA agencies are seeking a more comprehensive understanding of treatment value. Patients are rightly demanding that outcomes affecting daily life and wellbeing receive appropriate consideration.

As a result, sponsors face increasing pressure to demonstrate not only that a treatment achieves a statistically significant result, but also that it delivers meaningful benefits when viewed in the context of all clinically important outcomes.

This shift reflects a broader evolution in healthcare decision-making. Success is no longer defined solely by performance on a primary endpoint. It is increasingly defined by a treatment’s overall impact on patients.

Looking beyond the p-value

Clinical relevance is ultimately about connecting clinical trial results to real-world decision-making.

A statistically significant result may be an important starting point, but it is rarely the final answer. Determining whether a therapy truly matters to patients requires consideration of efficacy, safety, quality of life, treatment burden, and other patient-relevant outcomes.

As decision-makers place greater emphasis on the totality of evidence, approaches capable of evaluating multiple dimensions of treatment benefit simultaneously are likely to become increasingly valuable.

The future of evidence generation will not be defined solely by whether a treatment works. It will be defined by whether that treatment delivers meaningful value when viewed through the lens of clinical relevance.

Frequently Asked Questions